Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer
Chang Gon Kim, Minkyu Jung, Hyo Song Kim, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 27, pp. 4394-4405
Closed Access | Times Cited: 25

Showing 25 citing articles:

Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline)
In‐Ho Kim, Seung Joo Kang, Wonyoung Choi, et al.
Journal of the Korean Gastric Cancer Association (2025) Vol. 25, Iss. 1, pp. 5-5
Closed Access | Times Cited: 5
HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments
Magdalena K. Scheck, Ralf–Dieter Hofheinz, Sylvie Lorenzen
Cancers (2024) Vol. 16, Iss. 7, pp. 1336-1336
Open Access | Times Cited: 13
HER2+ advanced gastric cancer: Current state and opportunities (Review)
Hui-Hui Hu, Saiqi Wang, Huichen Zhao, et al.
International Journal of Oncology (2024) Vol. 64, Iss. 4
Open Access | Times Cited: 9
HER2-low gastric cancer: is the subgroup targetable?
Keitaro Shimozaki, Shota Fukuoka, Akira Ooki, et al.
ESMO Open (2024) Vol. 9, Iss. 9, pp. 103679-103679
Open Access | Times Cited: 9
Deep learning-based prediction of HER2 status and trastuzumab treatment efficacy of gastric adenocarcinoma based on morphological features
Zhida Wu, Tao Wang, Junlin Lan, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Phase II trial of HER-Vaxx, a B cell peptide-based vaccine, in HER2-overexpressing advanced gastric cancer patients under platinum-based chemotherapy (HERIZON)
Joshua Tobias, Marina Maglakelidze, Zoran Andrić, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 18, pp. 4044-4054
Open Access | Times Cited: 7
Prediction of HER2 Expression in Gastric Adenocarcinoma Based On Preoperative Noninvasive Multimodal 18F-FDG PET/CT Imaging
Lilin Qin, Wujie Chen, Yuanxin Ye, et al.
Academic Radiology (2024) Vol. 31, Iss. 8, pp. 3200-3211
Closed Access | Times Cited: 6
Unveiling Promising Targets in Gastric Cancer Therapy: A Comprehensive Review
Wenke Li, Jing Wei, Mo Cheng, et al.
Deleted Journal (2024) Vol. 32, Iss. 3, pp. 200857-200857
Open Access | Times Cited: 5
Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond
In‐Ho Kim
Journal of the Korean Gastric Cancer Association (2023) Vol. 24, Iss. 1, pp. 29-29
Open Access | Times Cited: 10
Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights
Yu Aoki, Izuma Nakayama, Kohei Shitara
Current Oncology Reports (2025)
Closed Access
Reversal of chemotherapy resistance in gastric cancer with traditional Chinese medicine as sensitizer: potential mechanism of action
Chencong Zhou, Kaihan Wu, M. Gu, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Nab-paclitaxel combined with cadonilimab (AK104) as second-line treatment for advanced gastric cancer: protocol for a phase II prospective, multicenter, single-arm clinical trial
Jing Wei, Pengfei Zhang, Qiancheng Hu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial
Funda Meric‐Bernstam, Sun Young Rha, Erika Hamilton, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Treatment strategies for patients with HER2-positive gastric cancer
Feixue Wang, Yi Ba
Cancer Biology and Medicine (2024) Vol. 20, Iss. 12, pp. 934-941
Open Access | Times Cited: 3
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma
Harshabad Singh, Kristen E. Lowder, Kevin S. Kapner, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Varlitinib and Paclitaxel for EGFR/HER2 Co-expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13)
Dong‐Hoe Koo, Minkyu Jung, Yeul Hong Kim, et al.
Cancer Research and Treatment (2024) Vol. 56, Iss. 4, pp. 1136-1145
Open Access | Times Cited: 2
Recent Progress in Treatment for HER2-Positive Advanced Gastric Cancer
Takeshi Kawakami, Kentaro Yamazaki
Cancers (2024) Vol. 16, Iss. 9, pp. 1747-1747
Open Access | Times Cited: 1
Pembrolizumab in combination with trastuzumab for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer
Zaheer Qureshi, Abdur Jamil, Eeshal Fatima, et al.
Annals of Medicine and Surgery (2024) Vol. 86, Iss. 8, pp. 4647-4656
Open Access | Times Cited: 1
The addition of PD-1 inhibitor overcame trastuzumab resistance in patients with HER2 positive, PD-L1 negative metastatic gastric cancer: Case report and review of literature
Zhenpeng Wen, Daoli Ye, Qiancheng Hu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
The diagnostic and prognostic value of tsRNAs in gastric cancers: a systematic review and meta-analysis
Hua Gao, Qiankun Zhang, Weibing Wu, et al.
Expert Review of Molecular Diagnostics (2023) Vol. 23, Iss. 11, pp. 985-997
Closed Access | Times Cited: 2
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma
Aysegül Ilhan‐Mutlu, Ewald Wöll
memo - Magazine of European Medical Oncology (2023) Vol. 16, Iss. 4, pp. 237-241
Open Access | Times Cited: 1
Current and Emerging Therapeutic Options for Human Epidermal Growth Factor Receptor 2-Expressing Gastroesophageal Cancers
Eric S. Silberman, Anahi McIntyre, Lakshmi Rajdev
Advances in Oncology (2024) Vol. 4, Iss. 1, pp. 219-231
Closed Access
Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice
Maria Bonomi, Daniele Spada, Gian Luca Baiocchi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3876-3876
Open Access
High Expression of CLDN 18.2 is Associated with Poor Disease-Free Survival of HER-2 Positive Gastric Cancer
Tongxin Zhang, Zilong He, Yankui Liu, et al.
International Journal of General Medicine (2024) Vol. Volume 17, pp. 1695-1705
Open Access
Machine learning-based dynamic predictive models for prognosis and treatment decisions in patients with liver metastases from gastric cancer
Zhiqiang Wang, Xingqing Jia, Yukun Yang, et al.
American Journal of Cancer Research (2024) Vol. 14, Iss. 11, pp. 5521-5538
Closed Access
Page 1

Scroll to top